Mosaic ImmunoEngineering Inc.: Newly Published Data Further Support Mosaic ImmunoEngineering's Lead Immuno-Oncology Candidate MIE-101 in Combination with OX40 Checkpoint Treatment in Melanoma
Broad, durable, and systemic anti-tumor immunity observed using inCPMV with OX40 agonist antibodiesIntratumoral inCPMV administration in combination with systemic anti-OX40 controlled the progression of
Source: finanznachrichten.de
